Payment overview · 2025
General Payments
$76,869.23
111 reported records · 19 companies
Healthcare provider profile · identity verified
Devin Sherman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FRANKLIN, TN · NPI 1659497592
Verified facts
What the public records show
CMS Open Payments records show Devin Sherman, MD received $76,869.23 in general payments during 2025 across 111 reported records.
AstraZeneca Pharmaceuticals LP accounted for 71.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55,152.84 | 71.8% | 53 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $20,187.61 | 26.3% | 16 | 2025 |
| Elucent Medical | Unresolved — no canonical attribution shown | $450.00 | 0.6% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $176.81 | 0.2% | 7 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $149.41 | 0.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $147.93 | 0.2% | 12 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $114.77 | 0.1% | 4 | 2025 |
| Ethicon Inc. | Unresolved — no canonical attribution shown | $106.79 | 0.1% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $50.55 | 0.1% | 2 | 2025 |
| ERBE USA Inc | Unresolved — no canonical attribution shown | $50.00 | 0.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $48.44 | 0.1% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $45.89 | 0.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.52 | 0.1% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $31.06 | 0.0% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $30.61 | 0.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.19 | 0.0% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $25.46 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.46 | 0.0% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $13.89 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $71,940.00 | 27 |
| Food and Beverage | $2,638.23 | 70 |
| Travel and Lodging | $1,841.00 | 13 |
| Consulting Fee | $450.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $54,906.39 | 49 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $20,364.42 | 23 | 2025 |
Source payment records
|
|||||
| Progel Applicator Spray Tips Normalized: progel applicator spray tips |
Device | Davol Inc. | $149.41 | 1 | 2025 |
Source payment records
|
|||||
| Monarch Platform Normalized: monarch platform |
Device | Ethicon Inc. | $106.79 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $91.44 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $84.72 | 3 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $77.12 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $71.47 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $70.81 | 3 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $50.55 | 2 | 2025 |
Source payment records
|
|||||
| cryo2 Normalized: cryo2 |
Device | ERBE USA Inc | $50.00 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $48.44 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $45.89 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $31.06 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $30.61 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $30.61 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $30.05 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $25.46 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $11.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 15 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 222 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
222 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
182 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 263 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 252 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 222 | 55 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 221 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 220 | 79 |
| Eliquis | Apixaban | 182 | 28 |
| Furosemide | Furosemide | 178 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 163 | 30 |
| Azithromycin | Azithromycin | 145 | 63 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 117 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 109 | 28 |
| Lisinopril | Lisinopril | 106 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 104 | 23 |
| Donepezil Hcl | Donepezil Hcl | 98 | 15 |
| Sertraline Hcl | Sertraline Hcl | 96 | 21 |
| Losartan Potassium | Losartan Potassium | 88 | 24 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 82 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 14 |
| Mirtazapine | Mirtazapine | 80 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 18 |
| Spiriva Respimat | Tiotropium Bromide | 68 | 16 |
| Methylprednisolone | Methylprednisolone | 63 | 54 |
| Carvedilol | Carvedilol | 56 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 56 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 56 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 56 | 16 |
| Allopurinol | Allopurinol | 55 | suppressed |
| Potassium Chloride | Potassium Chloride | 54 | suppressed |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 48 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 17 |
| Trazodone Hcl | Trazodone Hcl | 45 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 20 |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Omeprazole | Omeprazole | 43 | suppressed |
| Dulera | Mometasone/Formoterol | 41 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | suppressed |
| Roflumilast | Roflumilast | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | 11 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Xolair | Omalizumab | 28 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 27 | suppressed |
| Dupixent Pen | Dupilumab | 26 | suppressed |
| Gabapentin | Gabapentin | 26 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 26 | 15 |
| Alprazolam | Alprazolam | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Metformin Hcl | Metformin Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 15 |
| Lidocaine | Lidocaine | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Dupixent Syringe | Dupilumab | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Xopenex Hfa | Levalbuterol Tartrate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $76,869.23 · 111 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Arikayce, BREZTRI, Brinsupri, COMIRNATY, DUPIXENT, FARXIGA, Flexitouch Plus, HYQVIA, Hillrom - Vest System Model 105 Home Care, Hizentra, Monarch Platform, NUCALA, Nimbl, Ohtuvayre, PREVNAR 20, Progel Applicator Spray Tips, TEZSPIRE, TRELEGY ELLIPTA, Tyvaso, Vest Therapy Und, cryo2 | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error